Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnostic benefits of adding EspC, EspF and Rv2348-B to the QuantiFERON Gold In-tube antigen combination

  • Villar-Hernández, Raquel|||0000-0002-2249-0579
  • Blauenfeldt, Thomas
  • García-García, Esther
  • Muriel-Moreno, Beatriz|||0000-0002-6683-9082
  • De Souza Galvão, Maria Luiza|||0000-0001-9703-989X
  • Millet, Joan Pau|||0000-0003-0200-2459
  • Sabriá, Fina
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Ruiz Manzano, Juan|||0000-0001-7213-7346
  • Pilarte, Jose
  • Jiménez, M. A.
  • Centeno, Carmen
  • Martos, Carmen
  • Molina-Pinargote, Israel|||0000-0002-9160-0284
  • González, Yoel-Domingo|||0000-0002-5991-8938
  • Santiago, Javier
  • Cantos, Adela
  • Casas, Irma|||0000-0002-5902-5777
  • Guerola, Rosa
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Andersen, Peter Lawætz
  • Latorre, Irene|||0000-0001-8159-2455
  • Ruhwald, Morten|||0000-0002-1597-441X
  • Domínguez, José|||0000-0001-7888-0309
Interferon (IFN)-γ release assays (IGRAs) are used to diagnose latent tuberculosis (TB) infection (LTBI). To improve the accuracy of these tests, different approaches, such as alternative cytokine detection and using different antigens, are considered. Following this purpose, this study aims to evaluate the addition of EspC, EspF and Rv2348-B to those present in the QuantiFERON-TB Gold In-Tube (QFN-G-IT). We included 115 subjects: 74 active TB patients, 17 LTBI individuals and 24 healthy controls. Whole blood samples were collected in QFN-G-IT and in-house tubes containing different combinations of EspC, EspF and Rv2348-B, together with ESAT-6, CFP-10, and TB7.7. After overnight incubation at 37 ºC, plasma was harvested and IFN-γ quantified. IFN-γ levels in the QFN-G-IT and in-house tubes correlated very good (Spearman Rho(r).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk of SARS-CoV-2 Infection in Previously Infected and Non-Infected Cohorts of Health Workers at High Risk of Exposure

  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Fernandez-Naval, Candela|||0000-0002-5584-3537
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Durà-Miralles, Xavier
  • Vimes, Alba
  • Silgado, Aroa|||0000-0001-7581-0049
  • Velásquez-Orozco, Fernando
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Almirante Gragera, Benito|||0000-0002-1189-2361
  • Esperalba, Juliana|||0000-0003-1326-1341
The objective of this study is to assess the risk of newly acquired RNA detection-proven SARS-CoV-2 infection after previous SARS-CoV-2 infection. This is a prospective study conducted from March to September 2020 in Barcelona, Spain. Healthcare workers caring for SARS-CoV-2 infected patients were divided in two cohorts: (a) previously RNA-proven SARS-CoV-2 infected cohort with mild symptoms (IC) and (b) healthy cohort (HC). Weekly SARS-CoV-2 RNA detection assays from nasopharyngeal swabs were performed. Serology status was assessed at the beginning and at the end of the study. Twenty participants were included in each group. The median age was 30 (IQR 27-34.75) years, and 55% were female. The median time of follow up was 49 (IQR 49-51) days. Fifteen out of 246 (6%) nasopharyngeal swab samples were positive for SARS-CoV-2, all in the IC. The percentage of participants in the IC with a probable newly acquired SARS-CoV-2 RNA-proven infection was 20% (95% IC 5.7-43.6%) at the end of the 7-week follow up period. The incidence reinfection rate was 28.6 (95% IC 7.8-73.2) cases per 1000 person-week. Despite detectable IgG antibodies against SARS-CoV-2 participants highly exposed to SARS-CoV-2 may develop a newly acquired SARS-CoV-2 RNA detection episode during the first months after the initial infection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MDR Tuberculosis Treatment

  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Aznar, Maria Luisa|||0000-0001-9223-7790
  • Espiau, María|||0000-0001-9697-7649
Multidrug-resistant (MDR) tuberculosis (TB), resistant to isoniazid and rifampicin, continues to be one of the most important threats to controlling the TB epidemic. Over the last few years, there have been promising pharmacological advances in the paradigm of MDR TB treatment: new and repurposed drugs have shown excellent bactericidal and sterilizing activity against Mycobacterium tuberculosis and several all-oral short regimens to treat MDR TB have shown promising results. The purpose of this comprehensive review is to summarize the most important drugs currently used to treat MDR TB, the recommended regimens to treat MDR TB, and we also summarize new insights into the treatment of patients with MDR TB.